AsymBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), took center stage at the Antibody Engineering & Therapeutics conference in San Diego, CA. The company's presence at this esteemed event underscored its commitment to advancing biologics development and manufacturing.Asymbio’s team of experts, Jiawen Xu, Ph.D, Senior Director; Jan Jiricek, Ph.D, Senior Director of Business Development; and Brian Dwyer, Ph.D, Director of Business Development, engaged with industry leaders and experts throughout the conference.AsymBio highlighted its deep expertise in the development and manufacturing of multi-modality bioconjugates and biologics. In the meantime, AsymBio showcased its AmigoCHO cell line development platform, which has continued to facilitate optimized production of diverse biologics. By spotlighting cutting-edge technologies and manufacturing capabilities, AsymBio reinforced its dedication to advancing biologics innovation to commercialization.To learn more about AsymBio and its integrated solutions, visit our website for more information.

Under the leadership of the CTO, Dr. Kai Gao, the AsymBio's team embarked on a two-day team building at Mount Huangshan. This event provided an opportunity for the team to relax, rejuvenate, and build lasting connections between team members.

Asymchem Group (Stock Codes: 002821.SZ/6821.HK, hereinafter referred to as ＂Asymchem＂) and GeneQuantum Healthcare Co. Ltd. successfully signed a strategic cooperation agreement on April 18th. Both parties aim to leverage their respective strengths to accelerate the development of the ADC industry and address unmet clinical needs. Representatives from Asymchem Group, including Ms. Rui Yang, Co-CEO; Dr. Xinhui Hu, CTO & CBO; Mr. Yingwei Jiang, Executive Vice President; Dr. Kai Gao, Vice President and CTO of AsymBio; and Mr. Xian Zhang, Vice President of the Marketing Department, attended the signing ceremony.Following the signing of this strategic cooperation agreement, Asymchem Group will fully utilize its one-stop CMC service advantages. Through its advanced technical capabilities, rigorous quality management system, and lean operational support system, Asymchem will assist in the research and development transformation and commercialization of multiple ADC projects for GeneQuantum, offering a comprehensive one-stop CMC service including clinical sample supply, BLA filing, and commercial production. This will not only enhance the efficiency of innovative biopharmaceutical research and development but also reduce costs, ultimately benefiting patients worldwide. Additionally, GeneQuantum Healthcare will grant Asymchem the use of its proprietary and globally leading enzyme-mediated site-specific conjugation core technology, providing CDMO services for projects utilizing the GeneQuantum conjugation technology platform. GeneQuantum Healthcare's independent and innovative enzyme-mediated site-specific conjugation technology system, combined with Asymchem's one-stop CMC service capabilities in the ADC drug field, comprehensive industrial technology platform, efficient project delivery capabilities, and a globally distributed customer base, will undoubtedly generate synergies that exceed the sum of their parts.In recent years, leveraging its competitive advantage in the small molecule field, Asymchem has facilitated the rapid development of new businesses such as chemical macromolecules, clinical research services, formulations, biologics, and synthetic biology technology. AsymBio, focusing on CDMO services for biologics, has benefited greatly from Asymchem's rich project experience and professional expertise in the payload-linker field. It offers a one-stop CMC service for ADC drugs, including antibody intermediate and bulk conjugation, as well as formulation filling. This service has garnered industry acclaim, with a strong emphasis on protecting customer intellectual property, supported by a robust quality system, a professional project team, reliable end-to-end project management, and competitive business advantages.In the future, both parties will deepen their cooperation model, realizing complementary advantages. They will collaborate to further develop the thriving ADC drug research and production field, accelerating the research and development and transformation of next-generation biopharmaceutical conjugation drugs, thereby driving innovation in the industry.

On April 4, 2023, AsymBio held its 2023 annual meeting in a combination of both online and offline formats. The meeting reaffirmed and conveyed the development strategies and plans for AsymBio in 2023. The company will rally around the guideline of ＂Technology-Driven, Market Expansion, Compliance-Focused, Delivery-First, Cost Reduction, and Efficiency Improvement＂ to drive high-quality, efficient, and high-standard development. Ms. Rui Yang, Co-CEO of Asymchem Group and CEO of AsymBio, Mr. Yingwei Jiang, Executive Vice President of Asymchem Group, Dr. Kai Gao, Vice President and CTO of AsymBio, and other top executives attended the meeting, along with all employees of AsymBio.Ms. Rui Yang, Co-CEO of Asymchem Group and CEO of AsymBio, outlined specific plans and requirements for AsymBio's development in 2023. She integrated the development plans of AsymBio into an overall analysis and consideration of industry and group development. She emphasized the importance of adhering to the ＂Technology-Driven, Market Expansion, Compliance-Focused, Delivery-First, Cost Reduction, and Efficiency Improvement＂ management guideline under the group's ＂Dual-Drive＂ strategy. The long-term development goal is to firmly establish the principles of ＂Technology-Driven, Customized Service, Excellent Quality, Outstanding Efficiency, and Global Leadership.＂ The focus will be on building and enhancing the core competitiveness of the GXP one-stop service platform for conjugated drugs, efficiently empowering customers, and ensuring the successful implementation of the group's ＂Dual-Drive＂ strategy at the AsymBio level.Dr. Kai Gao, Vice President and CTO of AsymBio, presented specific requirements for the company's work in 2023. He stressed the importance of embracing the group's technology-driven culture, emphasizing internal technology projects, showcasing excellent R&D case studies, and increasing the industry's influence. The goal is to drive continuous technological advancements and empower project execution. He also emphasized the need to implement a comprehensive market expansion strategy, both in the front and back ends, by further expanding domestic and international markets. The management requirement of ＂Delivery-First＂ will be implemented by focusing on R&D, production, analysis, and other aspects. Dr. Gao also highlighted the need to improve compliance system construction and the daily management of compliance audits, reduce the proportion of raw materials to income, refine internal workflows, and establish cross-departmental collaboration mechanisms to achieve lean management in operational support.Mr. Yingwei Jiang, Executive Vice President of Asymchem Group, Ms. Ting Zhang, Executive Vice President of Asymchem Group, Mr. Ye Shi, Executive Vice President of Asymchem Group, and Mr. Jie Tian, Vice President of AsymBio, provided insights into development planning from the perspectives of human resources management, operational management systems, quality systems, and organizational capacity building for 2023. In 2023, all departments of AsymBio will focus on the management guideline, leveraging the mature management model and advanced experience accumulated by Asymchem Group over more than two decades. The emphasis will be on technology-driven efforts, continuous improvement of service efficiency, optimization of the quality system, and lean management in operational support. These efforts aim to drive the company to new heights.In conclusion, Ms. Rui Yang and Dr. Kai Gao delivered their closing remarks at the meeting. They emphasized that 2023 is the year when AsymBio will fully exert its efforts. Under the guidance of the group's ＂Dual-Drive＂ strategy, all employees of AsymBio should focus on the management guideline, unite with determination, work together, and strive for excellence. They should harness their collective energy to continuously reach new heights, create new prospects, and achieve breakthrough development.Strength arises from unity; wisdom guides our actions. The past year marked AsymBio's foundational year, and together with all employees' concerted efforts, it achieved remarkable results by serving 48 projects. Long-term corporate development relies on sound strategic judgment and exceptional strategic determination. Through top-level planning and communication at this meeting, precise planning for AsymBio's development direction and goals in 2023 was established. In the future, AsymBio will stand at a new starting point, achieve comprehensive enhancements in operational support, organizational development, quality systems, and business capabilities, serve more innovative biopharmaceutical companies, and better empower and accelerate the research and development transformation of innovative drugs.

Asymchem Group (Stock Codes: 002821.SZ, 6821.HK, hereinafter referred to as ＂Asymchem＂) and Ausper Biopharma, Inc (hereinafter referred to as ＂AusperBio＂) recently signed a strategic cooperation agreement. This strategic partnership marks a new beginning for both companies, with a focus on mutually beneficial collaboration in new drug research and development technology services, pharmaceutical regulatory consulting, brand promotion, and more. Asymchem, leveraging its years of technical expertise and extensive experience, will work closely with the Haobo Pharmaceutical team to accelerate and facilitate the market entry of valuable innovative drugs.Present at the signing ceremony, conducted through a combination of online and offline channels, were Dr. Guofeng Cheng, CEO of AusperBio; Dr. Chengyong Yang, CSO; Dr. Yang Tian, SVP; Mr. Xiaofang Fang, Executive Director; Dr. Xinhui Hu, CTO & CBO of Asymchem Group; Dr. Kai Gao, Vice President and CTO of AsymBio; and Mr. Xian Zhang, Vice President of the Marketing Department, along with representatives from both business teams.The strategic partnership between Asymchem and AusperBio encompasses a wide range of one-stop services, including but not limited to the development and optimization of processes/formulations for active pharmaceutical ingredients and finished products in areas such as small molecules, small nucleic acids, and biologics, as well as research and development of new varieties, clinical sample supply, commercial supply, drug-related pharmacokinetic and toxicological studies, clinical services, and regulatory consulting on pharmaceutical policies and regulations. The collaboration will initially focus on activities related to clinical supply, project management, MAH business, drug-related pharmacokinetic and toxicological research, IND registration, and more within AusperBio's ongoing projects.This strategic collaboration not only strengthens the existing partnership between Asymchem and Haobo Pharmaceutical but also serves as a fresh starting point for deeper cooperation. In fact, the two parties have already established a strong foundation for collaboration and successfully executed multiple projects across various sectors. For example, in October 2022, AsymBio, a subsidiary of Asymchem, specializing in biologics CDMO, leveraged its advanced technological capabilities, professional service levels, and efficient one-stop project management experience to assist AusperBio and its joint venture company, Mingdao Haoyue, in obtaining clinical approval for the intranasal COVID-19 neutralizing antibody MY-586. In this project, Asymchem provided comprehensive services ranging from MY-586 research and production to clinical application. Through joint efforts, MY-586 received clinical research approval from the Chinese regulatory authorities in just 13 months, with production from DNA to toxicology and GMP batch liquid and formulation taking only 8 months.In recent years, while consolidating its position in the small molecule CDMO main track, Asymchem has continuously expanded its service offerings into new areas such as chemical macromolecules, biological macromolecules, synthetic biology, and clinical CRO, creating new sources of robust growth for the company. Additionally, Asymchem has been building a GXP one-stop service engine, covering small molecule APIs, chemical macromolecules, biologics, formulations, pharmacology/pharmacokinetics/toxicology, clinical research, and regulatory application, among other services. Through a virtual project management matrix, seamless integration of various business modules is ensured, coupled with strong technical support, thus saving time and costs for customers and efficiently empowering and accelerating the research and development transformation process of innovative drugs.With this elevated starting point in their strategic collaboration, Asymchem and AusperBio are poised for a formidable alliance, complementing each other's strengths and deepening their cooperation. This partnership aims to create greater economic and social benefits, continually improve unmet clinical needs, and join hands to benefit patients worldwide.